Esophageal Cancer Clinical Trial
— POP-UPOfficial title:
Trimodal Peri Operative Prehabilitation for Upper Oesogastric and Pancreatic Cancer: A Multicenter, Two-cohort, Open-label, Single-arm POP-UP GERCOR Study
This is a multicenter, two-cohort, open-label, single-arm feasibility study. The primary objective is to assess the feasibility of the 8-week trimodal prehabilitation program alongside perioperative triplet chemotherapy in eligible patients with localized pancreatic ductal adenocarcinoma (PDAC) or oesogastric cancer (OGC) .
Status | Not yet recruiting |
Enrollment | 72 |
Est. completion date | March 2027 |
Est. primary completion date | March 2027 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: - Signed and dated patient informed consent form (ICF) and willingness to comply with all study procedures and availability for the study duration, - Histologically or cytologically localized PDAC or OGC validated by the multidisciplinary team, - Indication to a preoperative treatment withtriplet chemotherapy for = 4 cycles (8 weeks), Note: Patient treated for PDAC, first cycle without oxaliplatin is authorized. - Age > 18 years; If aged = 75 years: G8 score must be = 14 and if < 14 validation of oncogeriatric specialist, - Eastern Cooperative Oncology Group performance status (ECOG PS) of 0-1 at inclusion visit (first prehabilitation hospital-day), - No prior treatment for PDAC or OGC before screening visit, - At least one measurable or evaluable lesion as assessed by Computerized Tomography scan or Magnetic resonance imaging according to RECIST 1.1 and feasibility of repeated radiological assessments on baseline imaging before starting chemotherapy, - Adequate hematologic and end-organ function allowing the triple combination chemotherapy protocol, - Registration in a national health care system (PUMa - Protection Universelle Maladie included). Exclusion Criteria: - Evidence of metastatic disease at imaging (validated in multidisciplinary team evaluation), - Histology of other than adenocarcinoma, - Any medical (including cardiovascular, respiratory, psychiatric, musculoskeletal, or neurological) condition contra-indicating exercise practice, - Patients with medical contraindication to surgery due to general condition or comorbidities - Pregnancy or breast-feeding, - Patient under a legal protection regime (guardianship, curatorship, judicial safeguard) or administrative decision or incapable of giving his/her consent, |
Country | Name | City | State |
---|---|---|---|
n/a |
Lead Sponsor | Collaborator |
---|---|
GERCOR - Multidisciplinary Oncology Cooperative Group |
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Rate of patients with successful completion of an 8-week trimodal prehabilitation program | The success of prehabilitation is defined by the achievement of the following three criteria:
Completion of at least 75% of the planned APA sessions: 6 of 8 sessions with an APA professional and 12 of 16 sessions in autonomy with remote APA supervision and Completion of at least 75% of the nutritional evaluations: 6 of 8 planned evaluations and Psychological or psychiatric visit before the surgery in function of practice center /resources if a psychological need is shown by Hospital Anxiety and Depression Scale |
8 weeks | |
Secondary | Success rate (as defined above) for Adapted Physical Activity (APA), nutritional, and psychological interventions measured separately. | The success of APA, nutritional, and psychological interventions analyzed separately | 8 weeks | |
Secondary | Health-related quality of life (HRQoL) assessment | HRQoL assessed using the EORTC Core Quality of Life questionnaire (EORTC QLQ-C30) questionnaire for all patients. | Up to 3 years | |
Secondary | Rate of patients who start and complete post-habilitation Adapted Physical Activity (APA) sessions | Rate of patients who start and complete post-habilitation APA sessions; reasons for drop-out. | 8 weeks | |
Secondary | Nutritional status assessment | Nutritional status assessment by:
Body mass index (BMI) - BMI will be calculated by dividing mass in kilograms (kg) by height in meters squared (m2). Food intake will be measured by visual analog scale SEFI [Score d'Evaluation Facile des Ingesta=Ingesta Easy Evaluation Score]). The SEFI is a score rated from 0 (nothing is consumed) to 10 (everything is consumed) in whole numbers. A SEFI < 7/10 corresponds to decreased food intake and is associated with risk of malnutrition. A SEFI = 7 corresponds to satisfactory food intake. |
8 weeks | |
Secondary | Physical/functional test assessment | Functional tests: 6-minute waking test, handgrip test, one minute sit-to-stand (STS), assessment of Borg scale post physical exercise will be measured.
A 6-minutes walking test (distance measured in meters) will be performed. Dyspnea will be measured by the Borg scale Borg scale (ratings of the effort to breathe; a scale from 0 to 10, where 0 represents no dyspnea and 10 represents maximal dyspnea). Scores are obtained at the end of the walking test and reflect the maximum degree of dyspnea at any time during the walk test. Handgrip test - hand grip strength will be measured using dynamometer in sitting position and will be expressed in kilograms (kg). One-minute sit-and-stand test - Patients will perform stand-and-sit transitions on the chair as many times as possible within one minute. Number of of repetitions will be measured. |
8 weeks | |
Secondary | Number of patients with reduced chemotherapy tolerance | Chemotherapy tolerance: toxicities (Common Terminology Criteria for Adverse Events [CTCAE] v5.0) of grade = 3, toxicities requiring hospitalization, treatment delays or dose reduction due to toxicities | 8 weeks | |
Secondary | Number of patients with chemotherapy dose modification | Modification of the chemotherapy related dose-intensity relation on the completion or not of the prehabilitation program | 8 weeks | |
Secondary | Rate of patients who complete the strategy | Rate of patients who undergo surgery and the total number of planned perioperative chemotherapy cycles, and number of cycles received / number of cycles planned | 8 weeks | |
Secondary | Number of patients with Granulocyte-colony stimulating factor (G-CSF) prescription and grade = 2 neutropenia | rate of patients' with GCSF prescription and grade = 2 neutropenia | 8 weeks | |
Secondary | Rate of patients with exocrine pancreatic insufficiency and the dose of pancreatic enzyme consumption | Preoperative and post-operative fecal elastase and pancreatic enzymes prescription and reported consumption | 8 weeks | |
Secondary | Rate of surgical complications | Rate of surgical complications requiring reintervention or rehospitalisation (grade = 3 in Clavien-Dindo classification) within 90 days after surgery, length of hospital stay | At 30 days after surgery | |
Secondary | Overall survival (OS) assessment | OS defined as time between the date of inclusion and 12 months after surgery | From inclusion up to 12 months after surgery | |
Secondary | Disease-free survival (DFS) assessment | DFS defined as the time between the date inclusion and the date corresponding at 12 months after surgery | From inclusion up to 12 months after surgery | |
Secondary | Adherence to Adapted Physical Activity (APA) program assessment | Adherence to the APA program: by patient reported outcomes collected via Activiti® app and the APA professional assessment | 8 weeks | |
Secondary | Physical activity behavior changes assessment | Simplified International Physical Activity Questionnaire (IPAQ-S) will be administrated to assess physical activity and sedentary behavior changes.
It is a 7-item questionnaire in which duration (hours and minutes per day), frequency (times per week), and intensity (walking, moderate and vigorous) of the previous 7 days will be collected. Sedentary time (self-reported time spent sitting) in the same time period will be recorded (hours/min/day). |
8 weeks | |
Secondary | Nurse coordination | Nurses will evaluate chemotherapy tolerance with the CTCAE V5.0 (Grade = 3) and weight lose once per week with Activiti® application. | 8 weeks |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT06006390 -
CEA Targeting Chimeric Antigen Receptor T Lymphocytes (CAR-T) in the Treatment of CEA Positive Advanced Solid Tumors
|
Phase 1/Phase 2 | |
Terminated |
NCT01624090 -
Mithramycin for Lung, Esophagus, and Other Chest Cancers
|
Phase 2 | |
Recruiting |
NCT05787522 -
Efficacy and Safety of AI-assisted Radiotherapy Contouring Software for Thoracic Organs at Risk
|
||
Not yet recruiting |
NCT05542680 -
Study on the Design and Application of Special Semi Recumbent Cushion for Postoperative Patients With Esophageal Cancer
|
N/A | |
Completed |
NCT03384511 -
The Use of 18F-ALF-NOTA-PRGD2 PET/CT Scan to Predict the Efficacy and Adverse Events of Apatinib in Malignancies.
|
Phase 4 | |
Completed |
NCT00003864 -
Docetaxel Plus Carboplatin in Treating Patients With Advanced Cancer of the Esophagus
|
Phase 2 | |
Recruiting |
NCT05491616 -
Nivolumab During Active Surveillance After Neoadjuvant Chemoradiation for Esophageal Cancer: SANO-3 Study
|
Phase 2 | |
Active, not recruiting |
NCT04383210 -
Study of Seribantumab in Adult Patients With NRG1 Gene Fusion Positive Advanced Solid Tumors
|
Phase 2 | |
Completed |
NCT00199849 -
NY-ESO-1 Plasmid DNA (pPJV7611) Cancer Vaccine
|
Phase 1 | |
Completed |
NCT03756597 -
PAN-study: Pan-Cancer Early Detection Study (PAN)
|
||
Completed |
NCT00400114 -
Sutent Following Chemotherapy, Radiation and Surgery For Resectable Esophageal Cancer
|
Phase 2 | |
Completed |
NCT03652077 -
A Safety and Tolerability Study of INCAGN02390 in Select Advanced Malignancies
|
Phase 1 | |
Recruiting |
NCT04615806 -
The Value of Lymph Node Dissection of Indocyanine Green-guided Near-infrared Fluorescent Imaging in Esophagectomy
|
N/A | |
Active, not recruiting |
NCT04566367 -
Blue Laser Imaging (BLI) for Detection of Secondary Head and Neck Cancer
|
N/A | |
Active, not recruiting |
NCT03962179 -
Feasibility and Efficacy of a Combination of a SEMS and Vacuum Wound Treatment (VACStent)
|
N/A | |
Terminated |
NCT01446874 -
Prevention of Post-operative Pneumonia (POPP)
|
Phase 2/Phase 3 | |
Completed |
NCT03468634 -
Raman Probe for In-vivo Diagnostics (During Oesophageal) Endoscopy
|
N/A | |
Active, not recruiting |
NCT02869217 -
Study of TBI-1301 (NY-ESO-1 Specific TCR Gene Transduced Autologous T Lymphocytes) in Patients With Solid Tumors
|
Phase 1 | |
Completed |
NCT02810652 -
Perioperative Geriatrics Intervention for Older Cancer Patients Undergoing Surgical Resection
|
N/A | |
Recruiting |
NCT02544737 -
Apatinib for Metastatic Esophageal Cancer.
|
Phase 2 |